Drug Profile
Research programme: recombinant intravenous immunoglobulins - Sorrento Therapeutics
Alternative Names: rIVIG - Sorrento TherapeuticsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Sorrento Therapeutics
- Class Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Immunological disorders; Infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Immunological-disorders in USA (IV)
- 16 Jul 2016 No recent reports of development identified for research development in Infections in USA (IV)
- 08 Jan 2013 Early research in Immunological disorders in USA (IV)